Abstract: SA-PO108

Interferon-Inducible Protein 10 and Disease Activity in Patients with Systemic Lupus Erythematous and Lupus Nephritis: A Systematic Review and Meta-Analysis

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Puapatanakul, Pongpratch, Chulalongkorn University, Bangkok, Thailand
  • Chansritrakul, Sonchai, Chonburi Hospital, Chonburi, Thailand
  • Susantitaphong, Paweena, Chulalongkorn University, Bangkok, Thailand
  • Eiam-Ong, Somchai, Chulalongkorn University, Bangkok, Thailand
  • Praditpornsilpa, Kearkiat, Chulalongkorn University, Bangkok, Thailand

There has been increasing evidence regarding correlation between serum as well as urine interferon-inducible protein 10 (IP-10) and disease activity of systemic lupus erythematous (SLE) patients.


We conducted a comprehensive search on PubMed, Scopus, and Cochrane electronic database through the end of December 2016. All studies that measured serum or urine IP-10 using enzyme immunoassay (EIA) in SLE patients with or without lupus nephritis (LN) were retrieved. Meta-analysis of correlation between each test and disease activity was performed using a random-effects model.


Thirteen studies measured either serum or urine IP-10 levels in SLE/LN patients. However, only 9 and 4 studies provided adequate data of serum and urine IP-10 levels, respectively in 396 active SLE,175 active LN, 442 inactive SLE patients, and 310 non-SLE controls. Serum IP-10 levels were significantly higher in active SLE than in non-active SLE patients (mean difference [MD] 365.8 pg/mL, 95% CI 262.8 to 468.7, p < 0.001) but were indifferent between patients with active and non-active LN (MD 18.8 pg/mL, 95% CI -136.7 to 174.3, p = 0.813). Serum IP-10 also showed positive correlation with disease activity in SLE and LN patients (pooled r = 0.28, 95% CI 0.20 to 0.37, p < 0.001; pooled r = 0.26, 95% CI 0.08 to 0.43, p = 0.006; respectively). Urine IP-10 levels were comparable between active and non-active SLE patients (MD 2.44 pg/mgCr, 95% CI -0.50 to 5.38, p = 0.10) but were significantly higher in active LN patients compared to non-active LN patients (MD 4.57 pg/mgCr, 95% CI 1.68 to 7.47, p = 0.002). Urine IP-10 also had positive correlation with disease activity in SLE and LN patients (pooled r = 0.21, 95% CI 0.05 to 0.36, p = 0.011; pooled r = 0.40, 95% CI 0.13 to 0.62, p = 0.005; respectively).


Serum and urine IP-10 levels demonstrate positive correlation with disease activity in both SLE and LN patients. However, an increase in serum IP-10 is more pronounced in active SLE while urine IP-10 showed a significant increase mainly in active LN.